Navigation Links
Johns Hopkins Evidence-based Practice Center awarded $475,000 project
Date:8/17/2011

An estimated $25 billion is spent annually on treating chronic wounds on patients in the United States. These chronic wounds deeply affect the quality of life of more than six million people who have them. The most common types of chronic skin wounds and skin ulcers are related to venous disease (conditions related to or caused by veins that become diseased or abnormal). Many treatment options are available, but the quality of evidence showing which treatments work better than others is often lacking. It is hard to prove which treatments are effective and should be the standards of care.

The Agency for Healthcare Research and Quality (AHRQ) awarded the Johns Hopkins Evidence-based Practice Center a $475,000 project to carry out an extensive research review and create a scientific report to inform health care providers about effective state-of-the-art wound care. Through this project, the Johns Hopkins Wound Center and the Johns Hopkins Evidence-based Practice Center are conducting an evidence-based review of wound care to determine what is known and unknown about it, and to establish strategies of care that are proved to work.

Gerald Lazarus, M.D., founder of the Johns Hopkins Wound Center, and professor of dermatology and medicine at Johns Hopkins Bayview Medical Center, and Jonathan Zenilman, M.D., newly named director of the Wound Center and professor of medicine and chief of the Division of Infectious Diseases at Johns Hopkins Bayview, are co-principal investigators of this study. Working with Eric Bass, M.D., MPH, director of the Johns Hopkins Evidence-based Practice Center, a team of recognized experts are trying to find important clinical answers to help treat patients with chronic wounds.

"This research is a unique and important study that underscores the scientific credibility and intellectual honesty of the Wound Center," says Dr. Lazarus. "It's a great example of how translational research affects everyday lives. The inf
'/>"/>

Contact: Karen Tong
ktong4@jhmi.edu
410-550-0128
Johns Hopkins Medical Institutions
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Johns Hopkins scientists map genes for common form of brain cancer
2. Johns Hopkins scientists begin first-of-its-kind research to create blood platelets from stem cells
3. Johns Hopkins researchers discover how some breast cancers alter their sensitivity to estrogen
4. Informed-consent forms should be shortened, simplified, Johns Hopkins bioethicists confirm
5. More focus needed on mental health triage in disaster preparedness, Johns Hopkins bioethicists urge
6. Johns Hopkins School of Medicine grants $5 million to study cognitive disorders
7. Johns Hopkins School of Medicine postdoctoral fellows win awards
8. Johns Hopkins researchers develop safer way to make induced pluripotent stem cells
9. Johns Hopkins scientists crack genetic code for form of pancreatic cancer
10. Hospital shootings rare, but rate of other assults high, Johns Hopkins researchers find
11. Johns Hopkins researchers turn off severe food allergies in mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary ... Paul Kenis in the Institute of Genomic Biology ... Illinois Urbana-Champaign describe their recent work on subcellular ... of cell functions including energy metabolism, signaling, and ... regulating normal cellular behavior, redox status has been ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
(Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
(Date:4/17/2014)... NY, April 17, 2014U.S. military personnel who served ... impact" concussive traumatic brain injury (TBI) were compared ... for other medical reasons. Differences in measures of ... 6-12 months after injury are reported in an ... peer-reviewed journal from Mary Ann Liebert, Inc., publishers. ...
(Date:4/17/2014)... million older Americans suffer from depression, often brought on ... research a project that followed the lives of ... found that Internet use among the elderly can reduce ... , "That,s a very strong effect," said Shelia Cotten, ... and media who led the project. "And it all ...
Breaking Medicine News(10 mins):Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Internet use can help ward off depression among elderly 2
... A short-term, very-high dose regimen of the immune-suppressing drug ... in most of a small group of patients studied ... disease, Johns Hopkins researchers report. The findings in nine ... suggest new ways to treat a disease that tends ...
... Bulge with Hoodia and Bitter Orange, LOS ... fatty,and unhealthy coffee creamers, Java Solutions today announces ... creamer to start your day off,with a weight-loss ... of,French vanilla and non-fat buttercream with Hoodia, a ...
... to Solantic Board, JACKSONVILLE, Fla., June 10 ... urgent care, today announced,the appointment of Tom Scully ... a General Partner with New York City Private ... largest private equity investor in,healthcare. In addition, Mr. ...
... 10 Christine Carson Filipovich, a,graduate of Venture ... Nursing Resources, Inc., was honored last month with ... Bolton School of Nursing at,Case Western Reserve University ... an alumna or alumnus "who has demonstrated,outstanding leadership ...
... no longer just for doctors as PointOne ... WAUWATOSA, Wis., June 10 PointOne Systems, ... tool, known as,RedBox Technology, will begin providing reports ... dramatic change from the industry,s focus,on hospitals, research ...
... Information technology has the power,"to transform data ... Co. executive Carly Fiorina once explained., ... Ingenious Med,s IM Quality,Measures(TM), a software package ... capture, report, and submit quality performance,metrics. Physicians ...
Cached Medicine News:Health News:'HiCy' drug regimen reverses ms symptoms in selected patients 2Health News:'HiCy' drug regimen reverses ms symptoms in selected patients 3Health News:Leaner Coffee Creamer Boosts Metabolism and Curbs Appetite 2Health News:Healthcare Veteran Joins Solantic Board of Directors 2Health News:Nursing Entrepreneur Whose Business Career Was Spurred by Venture Training is Honored with Alumna Award from Case Western Reserve University 2Health News:PointOne Launches New Business Direction, Healthcare Analytics Beyond Hospitals 2Health News:Ingenious Med's IM Quality Measures(TM) Delivers Insight About Hospitalist Performance 2Health News:Ingenious Med's IM Quality Measures(TM) Delivers Insight About Hospitalist Performance 3Health News:Ingenious Med's IM Quality Measures(TM) Delivers Insight About Hospitalist Performance 4
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... 1, 2007 - Introgen Therapeutics, Inc.,(NASDAQ:INGN) reported promising ... novel investigational mda-7/IL-24 tumor,suppressor agent, in patients with ... were presented today at the,annual meeting of the ... 22-patient trial, INGN 241 induced killing in all ...
... Inc.,(TSX: TLN) announced today that preliminary data from ... cancer,patients was published in abstract form as part ... Meeting in Chicago,Illinois. In the Phase I dose ... two ovarian, one duodenal and one,glioma), that had ...
Cached Medicine Technology:Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 2Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 3Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 2Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 3
... Bringing together the best of both ... intraocular instrument is the latest addition ... lightweight Eraser bipolar cautery instruments for ... hemostasis with extrusion aspiration and backflush ...
...
...
...
Medicine Products: